Sign In
Buy PTGX
$129.89
-1.53 (-1.16%)
At Close: Jul 13, 2026
Best Momentum Stocks to Buy for July 13th
11:01am, Monday, 13'th Jul 2026
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
New Strong Buy Stocks for July 13th
04:26am, Monday, 13'th Jul 2026
FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.
New Strong Buy Stocks for July 9th
05:56am, Thursday, 09'th Jul 2026
PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
11:30am, Wednesday, 08'th Jul 2026
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
12:15pm, Tuesday, 07'th Jul 2026
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Protagonist Therapeutics Reports Granting of Inducement Awards
04:05pm, Wednesday, 01'st Jul 2026
NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accor
Protagonist Therapeutics Reports Granting of Inducement Awards
04:00pm, Tuesday, 16'th Jun 2026
NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in acco
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal
08:46am, Saturday, 13'th Jun 2026
Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, leveraging major pharma partners for commercialization without heavy infrastructure costs. ICOTYDE's FDA a
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:12pm, Wednesday, 10'th Jun 2026
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
07:05am, Thursday, 28'th May 2026
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
11:05am, Friday, 22'nd May 2026
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
12:56pm, Tuesday, 12'th May 2026
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 05'th May 2026
ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligibl
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
09:05am, Tuesday, 28'th Apr 2026
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 millio
